Daisuke Chujo
Kanazawa University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Daisuke Chujo.
Hypertension Research | 2007
Daisuke Chujo; Kunimasa Yagi; Akimichi Asano; Hiroaki Muramoto; Satoko Sakai; Akitsu Ohnishi; Miyuki Shintaku-Kubota; Hiroshi Mabuchi; Masakazu Yamagishi; Junji Kobayashi
Hypertension contributes to the occurrence and progression of cardiovascular diseases. The angiotensin II type 1 receptor blocker telmisartan is reported to activate the peroxisome proliferator–activated receptor γ and improve insulin sensitivity. We investigated the effects of telmisartan treatment on visceral fat, serum adiponectin and vascular inflammation markers in Japanese hypertensive patients. This was an open-label, non-controlled study. Twenty-eight essential hypertensive patients (22 men and 6 women; age 60.6±1.9 years; body mass index [BMI] 25.5±0.6 kg/m2) participated. Fat area was assessed with computerized tomography. All the subjects were started on telmisartan 40 mg/day, which was increased to 80 mg/day to achieve the blood pressure target of less than 130/80 mmHg. We assessed the visceral and subcutaneous fat areas, serum adiponectin levels, and vascular inflammation markers at baseline and 24 weeks of telmisartan treatment. There were significant reductions in visceral fat area (from 103.1±7.9 to 93.3±8.4 cm2, p<0.01) and pulse wave velocity (from 1,706±52 to 1,587±51 cm/s, p<0.01) at 24 weeks. In contrast, significant increases in serum high-density lipoprotein cholesterol (from 5.06±0.15 to 5.32±0.13 mmol/L, p<0.05) and adiponectin levels (from 8.27±0.76 to 9.13±0.81 μg/mL, p<0.05) were observed. Also, there were reductions in the interleukin-6 level (from 2.26±0.27 to 1.60±0.14 pg/mL, p<0.01). We also conducted these investigations in male subjects alone and similar findings were obtained for all of these parameters. In conclusion, telmisartan treatment was associated with an improvement of vascular inflammation, reductions in visceral fat and increases in serum adiponectin.
Journal of Clinical Lipidology | 2015
Hayato Tada; Masa-aki Kawashiri; Takuya Nakahashi; Kunimasa Yagi; Daisuke Chujo; Azusa Ohbatake; Yukiko Mori; Shunsuke Mori; Mitsuhiro Kometani; Hiroshi Fujii; Atsushi Nohara; Akihiro Inazu; Hiroshi Mabuchi; Masakazu Yamagishi; Kenshi Hayashi
BACKGROUND Although of interest, few data exist on the clinical characteristics of Japanese patients with an extremely high triglyceride level (≥ 1000 mg/dL). OBJECTIVE We assessed the clinical characteristics of Japanese patients with an extremely high triglyceride level. METHODS We investigated the presence of coronary artery disease, history of pancreatitis, the presence of fatty liver, and the potential causes of elevated triglyceride in Japanese subjects with an extremely high level of fasting triglyceride (≥ 1000 mg/dL) among 70,368 subjects whose serum triglyceride was measured for any reason at Kanazawa University Hospital from April 2004 to March 2014. RESULTS We identified 215 (0.31%) subjects (mean age, 46 years; male, 170, mean body mass index, 25 kg/m(2)) with severe hypertriglyceridemia. Among them, 4 (1.9%) subjects were classified as type I, 97 (45.1%) subjects were type IV, and 114 (53.0%) subjects were type V hyperlipidemia, according to Fredricksons classification. Among 215 subjects, 116 subjects (54.0%) drank alcohol, 58 (27.0%) showed heavy intake (≥ 60 g/d), and 64 (29.8%) subjects had diabetes. In total, 59 (27.4%) subjects had transient severe hypertriglyceridemia caused by corticosteroids (N = 19), antidepressant (N = 18), l-asparaginase and steroids for acute lymphoid leukemia (N = 15), hormone replacement therapy for breast cancer (N = 9), β-blocker (N = 5), hypothyroidism (N = 4), pregnancy (N = 4), and panhypopituitarism (N = 2). As many as 119 (55.3%) subjects exhibited fatty liver. Moreover, 12 (5.6%) and 17 (7.9%) subjects had a history of pancreatitis and coronary artery disease, respectively. CONCLUSIONS A variety of situations can cause severe hypertriglyceridemia. We suggest that potential secondary causes should be carefully assessed for such patients.
Journal of Diabetes Investigation | 2018
Nobuyuki Takahashi; Tetsuro Tsujimoto; Daisuke Chujo; Hiroshi Kajio
To compare the incidence rate of renal dysfunction between patients with fulminant type 1 diabetes and those with acute‐onset type 1 diabetes.
Diabetology international | 2018
Ayumi Tokunaga; Akihisa Imagawa; Hiroshi Nishio; Satoshi Hayata; Iichiro Shimomura; Norio Abiru; Takuya Awata; Hiroshi Ikegami; Yasuko Uchigata; Yoichi Oikawa; Haruhiko Osawa; Hiroshi Kajio; Eiji Kawasaki; Yumiko Kawabata; Junji Kozawa; Akira Shimada; Kazuma Takahashi; Shoichiro Tanaka; Daisuke Chujo; Tomoyasu Fukui; Junnosuke Miura; Kazuki Yasuda; Hisafumi Yasuda; Tetsuro Kobayashi; Toshiaki Hanafusa
Abrupt disease onset and severe metabolic disorders are main characteristics of fulminant type 1 diabetes. Diffusion-weighted magnetic resonance imaging (DWI) is an imaging technique that reflects restricted diffusion in organs and can detect mononuclear cell infiltration into the pancreas at the onset of the disease. Fourteen patients with fulminant type 1 diabetes who underwent abdominal magnetic resonance imaging were recruited for the measurement of apparent diffusion coefficient (ADC) values of the pancreas that were compared with those of 21 non-diabetic controls. The ADC values of all parts of the pancreas were significantly lower in fulminant type 1 diabetes than in controls (head, 1.424 ± 0.382 × 10−3 vs. 1.675 ± 0.227 × 10−3 mm2/s; body, 1.399 ± 0.317 × 10−3 vs. 1.667 ± 0.170 × 10−3 mm2/s; tail, 1.336 ± 0.247 × 10−3 vs. 1.561 ± 0.191 × 10−3 mm2/s; mean, 1.386 ± 0.309 × 10−3 vs. 1.634 ± 0.175 × 10−3 mm2/s) (p < 0.01). The best cut-off value indicated that the sensitivity was 86% and the specificity was 71% when using DWI, which was also efficient in two atypical patients with fulminant type 1 diabetes without elevated levels of exocrine pancreatic enzymes or with high HbA1c levels due to the preexistence of type 2 diabetes. The ADC values were significantly correlated to plasma glucose levels and arterial pH, and tended to increase with the lapse of time. DWI may be an additional tool for making an efficient diagnosis of fulminant type 1 diabetes.
Internal Medicine | 2017
Tomohiko Kikuchi; Daisuke Chujo; Kazuhisa Takahashi; Nobuyuki Takahashi; Yuuki Tanno; Mie Tonoike; Noriko Ihana; Tetsuro Tsujimoto; Akiyo Tanabe; Hiroshi Kajio
A 71-year-old woman previously diagnosed with reactive hypoglycemia was transferred to our emergency unit because of loss of consciousness. Her plasma glucose level was 27 mg/dL, and continuous glucose monitoring (CGM) revealed postprandial asymptomatic hypoglycemia. A hypervascular tumor was identified via computed tomography in the distal pancreas, and the diagnosis of insulinoma was confirmed using the selective arterial calcium stimulation test. Although no episodes of hypoglycemia were observed during CGM after resection, a pathological examination identified regional lymph node metastasis. It is important to consider insulinoma as a cause of postprandial hypoglycemia, and CGM is useful for evaluating treatment outcomes.
Journal of Atherosclerosis and Thrombosis | 2007
Yuko Katsuda; Akimichi Asano; Yuko Murase; Daisuke Chujo; Kunimasa Yagi; Junji Kobayashi; Hiroshi Mabuchi; Masakazu Yamagishi
Endocrine Journal | 2014
Naoko Ito; Kunimasa Yagi; Mitsuhiro Kawano; Yukiko Mori; Satoko Okazaki; Daisuke Chujo; Yoshiyu Takeda; Junji Kobayashi; Masakazu Yamagishi
Internal Medicine | 2004
Yuko Murase; Kunimasa Yagi; Masako Sugihara; Daisuke Chujo; Michiko Otsuji; Hiroaki Muramoto; Hiroshi Mabuchi
Diabetology international | 2018
Megu Yamaguchi Baden; Akihisa Imagawa; Norio Abiru; Takuya Awata; Hiroshi Ikegami; Yasuko Uchigata; Yoichi Oikawa; Haruhiko Osawa; Hiroshi Kajio; Eiji Kawasaki; Yumiko Kawabata; Junji Kozawa; Akira Shimada; Kazuma Takahashi; Shoichiro Tanaka; Daisuke Chujo; Tomoyasu Fukui; Junnosuke Miura; Kazuki Yasuda; Hisafumi Yasuda; Tetsuro Kobayashi; Toshiaki Hanafusa
Diabetes Therapy | 2018
Maya Matsushita; Daisuke Chujo; Mie Tonoike; Hiroshi Kajio